Eiger BioPharmaceuticals launch HDV campaign

Eiger BioPharmaceuticals' hepatitis delta (HDV) campaign has been launched across the country.
The campaign is designed to expand patient access to testing and bringing awareness to HDV patients who have a hepatitis B virus co-infection.
"Eiger is committed to playing a leading role in developing novel treatments for HDV infection, the most severe form of hepatitis, and building awareness of the need for widespread testing," Eiger Senior Vice President of Liver and Infectious Diseases Drug Development Eduardo Martins said. "The campaign represents an important step toward expanding and accelerating broad-scale HDV testing, and arming physicians and patients with information they need."  
"ARUP is a worldwide leader in innovative laboratory research and development," ARUP Laboratories President and CEO Edgar Braendle said. "ARUP's hepatitis delta viral load assay is the first commercially available test in the United States to quantify the amount of HDV RNA in blood.  This test allows clinicians to monitor the kinetics of HDV infections and adds to our broad suite of hepatitis tests.  We are delighted to partner with Eiger and the Hepatitis B Foundation on this campaign, consistent with our mission to expand access to high quality healthcare and diagnostic services."